Brain small vessel disease 1 with or without ocular anomalies (BSVD1) is the cerebrovascular-predominant, autosomal dominant phenotype of the COL4A1-related disorder spectrum. It is caused by heterozygous mutations in COL4A1, which encodes the alpha-1 chain of type IV collagen — a protein that, together with the alpha-2 chain (COL4A2), forms the [alpha1(IV)]2-alpha2(IV) heterotrimer that is a major structural component of nearly all basement membranes, including those of the cerebral microvasculature. The great majority of pathogenic variants are missense substitutions of a glycine residue within the Gly-X-Y collagenous triple-helical domain; these destabilize triple-helix folding and impair secretion of both mutant and co-assembled wild-type heterotrimers, producing a dual insult of intracellular collagen retention with endoplasmic-reticulum stress and extracellular basement-membrane insufficiency. The resulting cerebral small-vessel fragility manifests as porencephaly, perinatal and later-life intracerebral hemorrhage, ischemic (lacunar) stroke, diffuse leukoencephalopathy, cerebral microbleeds, dilated perivascular spaces, intracranial aneurysm, and migraine, with severity strongly modulated by environmental second hits such as birth trauma, head trauma, intense exercise, anticoagulation, and hypertension. Because type IV collagen is a ubiquitous basement-membrane protein, the disorder is pleiotropic: the "with ocular anomalies" qualifier reflects the frequent anterior-segment dysgenesis (Axenfeld-Rieger anomaly, congenital cataract, glaucoma) and retinal arterial tortuosity, and additional systemic features (nephropathy with hematuria and renal cysts, muscle cramps with elevated creatine kinase, cerebral aneurysms — the HANAC constellation, Raynaud phenomenon, cardiac arrhythmia, and hemolytic anemia) can co-occur. There is no disease-modifying therapy; management is risk reduction and supportive.
Ask a research question about Brain Small Vessel Disease 1 With Or Without Ocular Anomalies. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Brain Small Vessel Disease 1 With Or Without Ocular Anomalies:
name: Brain Small Vessel Disease 1 With Or Without Ocular Anomalies
category: Mendelian
creation_date: "2026-07-30T23:40:00Z"
synonyms:
- COL4A1-related brain small vessel disease
- Brain small vessel disease with hemorrhage
- Brain small vessel disease with Axenfeld-Rieger anomaly
- COL4A1 porencephaly
- Autosomal dominant porencephaly type 1
- BSVD1
description: >-
Brain small vessel disease 1 with or without ocular anomalies (BSVD1) is the
cerebrovascular-predominant, autosomal dominant phenotype of the COL4A1-related
disorder spectrum. It is caused by heterozygous mutations in COL4A1, which
encodes the alpha-1 chain of type IV collagen — a protein that, together with
the alpha-2 chain (COL4A2), forms the [alpha1(IV)]2-alpha2(IV) heterotrimer that
is a major structural component of nearly all basement membranes, including those
of the cerebral microvasculature. The great majority of pathogenic variants are
missense substitutions of a glycine residue within the Gly-X-Y collagenous
triple-helical domain; these destabilize triple-helix folding and impair
secretion of both mutant and co-assembled wild-type heterotrimers, producing a
dual insult of intracellular collagen retention with endoplasmic-reticulum stress
and extracellular basement-membrane insufficiency. The resulting cerebral
small-vessel fragility manifests as porencephaly, perinatal and later-life
intracerebral hemorrhage, ischemic (lacunar) stroke, diffuse leukoencephalopathy,
cerebral microbleeds, dilated perivascular spaces, intracranial aneurysm, and
migraine, with severity strongly modulated by environmental second hits such as
birth trauma, head trauma, intense exercise, anticoagulation, and hypertension.
Because type IV collagen is a ubiquitous basement-membrane protein, the disorder
is pleiotropic: the "with ocular anomalies" qualifier reflects the frequent
anterior-segment dysgenesis (Axenfeld-Rieger anomaly, congenital cataract,
glaucoma) and retinal arterial tortuosity, and additional systemic features
(nephropathy with hematuria and renal cysts, muscle cramps with elevated creatine
kinase, cerebral aneurysms — the HANAC constellation, Raynaud phenomenon, cardiac
arrhythmia, and hemolytic anemia) can co-occur. There is no disease-modifying
therapy; management is risk reduction and supportive.
disease_term:
preferred_term: brain small vessel disease 1 with or without ocular anomalies
term:
id: MONDO:0008289
label: brain small vessel disease 1 with or without ocular anomalies
parents:
- COL4A1-related disorder
- Hereditary cerebral small vessel disease
mappings:
mondo_mappings:
- term:
id: MONDO:0008289
label: brain small vessel disease 1 with or without ocular anomalies
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: >-
MONDO:0008289 is the exact disease concept — an autosomal dominant familial
porencephaly / brain small-vessel disease caused by mutation in COL4A1,
variably associated with ocular anomalies (OMIM:175780).
references:
- reference: PMID:20301768
title: "COL4A1-Related Disorders."
tags:
- GeneReviews
inheritance:
- name: Autosomal dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
COL4A1-related disorders are inherited in an autosomal dominant manner. Most
affected individuals have an affected parent, but a substantial fraction of
cases arise de novo (GeneReviews estimates at least 27%). Each child of an
affected individual has a 50% chance of inheriting the variant. Penetrance and
expressivity are highly variable, even within a family, and asymptomatic
obligate carriers with only white-matter changes on MRI are documented. The
founding mouse model behaves semidominantly.
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "COL4A1-related disorders are inherited in an autosomal dominant manner."
explanation: GeneReviews establishes autosomal dominant inheritance.
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "The proportion of cases caused by a de novo pathogenic variant is estimated to be at least 27%."
explanation: Quantifies the de novo fraction.
- reference: PMID:16107487
reference_title: "Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The last mutation was also present in an asymptomatic obligate carrier with white matter abnormalities on brain magnetic resonance imaging."
explanation: Documents reduced penetrance / variable expression in an obligate carrier.
genetic:
- name: COL4A1
relationship_type: CAUSATIVE
variant_origin: GERMLINE
gene_term:
preferred_term: COL4A1
term:
id: hgnc:2202
label: COL4A1
notes: >-
COL4A1 encodes the alpha-1 chain of type IV collagen. Approximately 90% of
pathogenic variants are missense substitutions of a glycine in the Gly-X-Y
repeat of the triple-helical collagenous domain; nonsense, splice, indel, and
start-codon variants also occur. Because the position of the substitution
within the molecule influences which phenotypes predominate, a
genotype-phenotype correlation exists: variants clustering in exons 24-25 are
associated with the HANAC systemic (renal/muscular/aneurysmal) phenotype, while
variants distributed more broadly are associated with severe porencephaly and
cerebral small-vessel disease. The obligate partner gene COL4A2 causes a closely
overlapping phenotype (brain small vessel disease 2), because the two chains
obligately co-assemble into a shared heterotrimer.
evidence:
- reference: PMID:27794444
reference_title: "Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations."
supports: SUPPORT
evidence_source: OTHER
snippet: "glycine (Gly) substitutions within the triple helical domain are the most common class of mutations."
explanation: Establishes glycine substitutions in the triple helix as the dominant variant class.
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We identified three closely located glycine mutations in exons 24 and 25 of the gene COL4A1, which encodes procollagen type IV alpha1."
explanation: Localizes the HANAC-associated variants to exons 24-25.
- reference: PMID:25719457
reference_title: "The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature."
supports: SUPPORT
evidence_source: OTHER
snippet: "Since 2005, COL4A1 mutations have been known as an autosomal dominant cause of hereditary porencephaly."
explanation: Establishes COL4A1 as the causative autosomal dominant gene.
mechanistic_hypotheses:
- hypothesis_group_id: intracellular_gain_of_function
hypothesis_label: Intracellular collagen retention and ER stress (gain-of-function)
status: CANONICAL
description: >-
Mutant heterotrimers are retained within the endoplasmic reticulum, triggering
ER stress and the unfolded protein response with reduced proliferation,
apoptosis, and cytotoxicity. In mouse models, intracellular accumulation of
mutant collagen in vascular endothelial cells and pericytes is a key trigger of
intracerebral hemorrhage, and an FDA-approved chemical chaperone reduces the
accumulation — evidence that the intracellular toxicity arm is a driver, not a
bystander.
evidence:
- reference: PMID:22209247
reference_title: "COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "two of the three putative mutations found in patients trigger ER stress and activate the unfolded protein response."
explanation: >-
Directly demonstrates ER stress and UPR activation for pathogenic collagen IV
variants; shown for COL4A2 but mechanistically applicable to COL4A1 because the
two chains form an obligate shared heterotrimer.
- reference: PMID:25753534
reference_title: "Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "We found that intracellular accumulation of mutant collagen in vascular endothelial cells and pericytes was a key triggering factor of ICH."
explanation: Establishes intracellular accumulation in vascular mural cells as a key ICH trigger.
- hypothesis_group_id: extracellular_matrix_insufficiency
hypothesis_label: Extracellular basement-membrane insufficiency (loss-of-function arm)
status: ALTERNATIVE
description: >-
Impaired secretion of both mutant and co-assembled wild-type heterotrimers
reduces the amount of functional collagen IV reaching the basement membrane,
producing structurally defective, fragile vascular basement membranes. This
extracellular-insufficiency arm operates alongside the intracellular
gain-of-function arm; their relative contributions vary by tissue, and
disentangling them remains an open mechanistic question with therapeutic
implications.
evidence:
- reference: PMID:15905400
reference_title: "Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "a semidominant mutation in the procollagen type IV alpha 1 gene (Col4a1) in mice, which inhibits the secretion of mutant and normal type IV collagen."
explanation: Establishes secretion impairment of both mutant and normal collagen IV.
pathophysiology:
- name: COL4A1 Glycine Substitution and Triple-Helix Destabilization
biological_scale: MOLECULAR
description: >-
A heterozygous COL4A1 variant — most often a glycine substitution within the
Gly-X-Y repeat of the triple-helical domain — disrupts the obligate glycine at
every third position that permits tight collagen triple-helix folding. Because
COL4A1 and COL4A2 co-assemble into a single [alpha1(IV)]2-alpha2(IV)
heterotrimer that is a major component of nearly all basement membranes, a
single mutant chain compromises the whole trimer (a dominant-negative /
antimorphic effect).
genes:
- preferred_term: COL4A1
term:
id: hgnc:2202
label: COL4A1
molecular_functions:
- preferred_term: extracellular matrix structural constituent
term:
id: GO:0005201
label: extracellular matrix structural constituent
evidence:
- reference: PMID:22914737
reference_title: "COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets."
supports: SUPPORT
evidence_source: OTHER
snippet: "Heterotrimers composed of collagen type IV alpha 1 (COL4A1) and alpha 2 (COL4A2) constitute one of the most abundant components of nearly all basement membranes."
explanation: Establishes the heterotrimer as a ubiquitous basement-membrane component.
- reference: PMID:27794444
reference_title: "Genotype-phenotype correlations in pathology caused by collagen type IV alpha 1 and 2 mutations."
supports: SUPPORT
evidence_source: OTHER
snippet: "COL4A1 and COL4A2 are extracellular matrix proteins that form heterotrimers and are present in nearly all basement membranes in every organ."
explanation: Supports the molecular identity and ubiquity of the collagen IV heterotrimer.
downstream:
- target: Impaired Collagen IV Secretion and ER Stress
description: >-
The misfolded triple helix cannot be secreted efficiently, retaining mutant
and co-assembled wild-type heterotrimers inside the cell.
causal_link_type: DIRECT
evidence:
- reference: PMID:15905400
reference_title: "Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "a semidominant mutation in the procollagen type IV alpha 1 gene (Col4a1) in mice, which inhibits the secretion of mutant and normal type IV collagen."
explanation: Directly links the mutation to impaired secretion of both mutant and normal collagen IV.
- name: Impaired Collagen IV Secretion and ER Stress
biological_scale: CELLULAR
description: >-
Retention of the malformed heterotrimer in the endoplasmic reticulum has two
consequences that jointly drive disease: intracellularly, ER accumulation
triggers ER stress and the unfolded protein response with reduced proliferation
and increased apoptosis (a cytotoxic gain of function); extracellularly, less
functional collagen IV reaches the basement membrane (a matrix insufficiency).
The retained collagen is degraded via the proteasome, and clearance capacity
appears to be a disease modifier.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
- preferred_term: pericyte
term:
id: CL:0000669
label: pericyte
biological_processes:
- preferred_term: response to endoplasmic reticulum stress
term:
id: GO:0034976
label: response to endoplasmic reticulum stress
modifier: INCREASED
evidence:
- reference: PMID:22209247
reference_title: "COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "these putative mutations cause intracellular accumulation of COL4A1 and COL4A2 at the expense of their secretion, which supports their pathogenecity."
explanation: >-
Demonstrates intracellular accumulation at the expense of secretion in a cellular
assay; the assayed variants are in COL4A2, applicable to COL4A1 via the obligate
shared heterotrimer.
- reference: PMID:24001601
reference_title: "Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "This intracellular accumulation led to ER stress, unfolded protein response activation, reduced cell proliferation and increased apoptosis."
explanation: >-
Establishes the ER-stress / UPR / apoptosis cascade from intracellular collagen
accumulation; demonstrated for a COL4A2 variant and applicable to COL4A1 via the
obligate shared heterotrimer.
downstream:
- target: Vascular Basement Membrane Fragility
description: >-
The combined intracellular toxicity and reduced basement-membrane deposition
produce structurally defective, fragile vascular basement membranes.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Reduced deposition of functional collagen IV into the vascular basement membrane
- ER-stress-mediated injury of endothelial cells and pericytes
evidence:
- reference: PMID:25753534
reference_title: "Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "We found that intracellular accumulation of mutant collagen in vascular endothelial cells and pericytes was a key triggering factor of ICH."
explanation: Links intracellular accumulation in vascular mural cells to hemorrhage.
- name: Vascular Basement Membrane Fragility
biological_scale: TISSUE
description: >-
Focal disruptions of vascular basement membranes weaken the vessel wall.
Because type IV collagen is present in the basement membranes of essentially
every organ, the defect is systemic, but the thin-walled cerebral
microvasculature is especially vulnerable, giving the brain-predominant
phenotype. Complex basement-membrane defects are demonstrable in kidney and
skin as well.
evidence:
- reference: PMID:25753534
reference_title: "Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "We found that Col4a1 mutations cause abnormal vascular development, which triggers small-vessel disease, recurrent hemorrhagic strokes, and age-related macroangiopathy."
explanation: Establishes abnormal vascular development as the tissue-level substrate of small-vessel disease.
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Histologic analysis revealed complex basement-membrane defects in kidney and skin."
explanation: Documents the multi-organ basement-membrane defect histologically.
downstream:
- target: Cerebral Small-Vessel Fragility and Hemorrhage
description: Cerebral microvascular basement-membrane weakness predisposes to hemorrhage and ischemia.
causal_link_type: DIRECT
evidence:
- reference: PMID:16598045
reference_title: "Role of COL4A1 in small-vessel disease and hemorrhagic stroke."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "a mutation in the mouse Col4a1 gene, encoding procollagen type IV alpha1, predisposes both newborn and adult mice to intracerebral hemorrhage."
explanation: Directly links the vascular defect to cerebral hemorrhage predisposition.
- target: Ocular Basement Membrane Dysgenesis
description: >-
The same basement-membrane defect disrupts development and integrity of ocular
anterior-segment and retinal vascular structures.
causal_link_type: DIRECT
evidence:
- reference: PMID:28237965
reference_title: "Genetic dissection of anterior segment dysgenesis caused by a Col4a1 mutation in mouse."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "COL4A1 mutations cause multi-system disorders in patients, including ASD (congenital cataracts, Axenfeld-Rieger's anomaly, Peter's anomaly and microphthalmia) and congenital or juvenile glaucoma."
explanation: Links the collagen IV defect to the ocular anterior-segment dysgenesis spectrum.
- target: Renal and Muscular Basement Membrane Involvement
description: >-
Glomerular, tubular, and muscle basement-membrane defects produce the HANAC
systemic constellation.
causal_link_type: DIRECT
evidence:
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The clinical renal manifestations of the HANAC syndrome in these families include hematuria and bilateral, large cysts."
explanation: Links basement-membrane involvement to the renal HANAC phenotype.
- name: Cerebral Small-Vessel Fragility and Hemorrhage
biological_scale: ORGANISM
description: >-
Fragile cerebral small vessels give the defining brain phenotype: antenatal and
perinatal hemorrhage that resorbs into porencephalic cavities, later-life
recurrent intracerebral hemorrhage, lacunar (ischemic) infarction, diffuse
leukoencephalopathy, cerebral microbleeds, dilated perivascular spaces,
intracranial aneurysm, and migraine. A recurring theme is that hemorrhage is
frequently precipitated by an environmental "second hit" — birth trauma, head
trauma, intense physical activity, anticoagulation, or hypertension — on top of
the constitutional vascular fragility.
evidence:
- reference: PMID:16598045
reference_title: "Role of COL4A1 in small-vessel disease and hemorrhagic stroke."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "persons with COL4A1 mutations may be predisposed to hemorrhage, especially after environmental stress."
explanation: States the constitutional-fragility-plus-environmental-trigger model for hemorrhage.
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hemorrhages, often recurrent, have been associated with physical trauma and activity and anticoagulant therapy."
explanation: Documents the environmental precipitants of hemorrhage in human carriers.
downstream:
- target: Porencephaly
description: Resorption of perinatal cerebral hemorrhage leaves fluid-filled porencephalic cavities.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- Perinatal intracerebral hemorrhage with subsequent tissue cavitation
evidence:
- reference: PMID:16107487
reference_title: "Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This observation confirms COL4A1 as a major locus for genetic predisposition to perinatal cerebral haemorrhage and porencephaly"
explanation: Links COL4A1-driven perinatal hemorrhage to porencephaly.
- target: Intracerebral hemorrhage
description: Small-vessel wall fragility causes antenatal, perinatal, and later-life hemorrhage.
causal_link_type: DIRECT
evidence:
- reference: PMID:16598045
reference_title: "Role of COL4A1 in small-vessel disease and hemorrhagic stroke."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "predisposes both newborn and adult mice to intracerebral hemorrhage."
explanation: Establishes hemorrhage across the lifespan.
- name: Ocular Basement Membrane Dysgenesis
biological_scale: TISSUE
description: >-
Type IV collagen is required for normal development and maintenance of ocular
basement membranes. Its disruption produces anterior-segment dysgenesis
(Axenfeld-Rieger anomaly, congenital cataract, Peters anomaly, microphthalmia),
secondary congenital/juvenile glaucoma, and retinal arterial tortuosity — the
"ocular anomalies" of the disease name. In mouse models, the cataract arises
from a lens-autonomous requirement for collagen IV.
evidence:
- reference: PMID:17696175
reference_title: "COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diffuse leukoencephalopathy associated with ocular malformations of the Axenfeld-Rieger type was observed in five individuals."
explanation: Human family co-segregating Axenfeld-Rieger ocular malformation with leukoencephalopathy.
- reference: PMID:28237965
reference_title: "Genetic dissection of anterior segment dysgenesis caused by a Col4a1 mutation in mouse."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "50-75% of patients with ASD develop early onset and aggressive glaucoma."
explanation: Links the anterior-segment dysgenesis to secondary glaucoma risk.
downstream:
- target: Axenfeld-Rieger anomaly
description: Anterior-segment dysgenesis of the Axenfeld-Rieger type.
causal_link_type: DIRECT
evidence:
- reference: PMID:17696175
reference_title: "COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We delineate a novel association between the Axenfeld-Rieger anomaly and leukoencephalopathy and stroke."
explanation: Establishes the Axenfeld-Rieger association directly.
- name: Renal and Muscular Basement Membrane Involvement
biological_scale: TISSUE
description: >-
Glomerular and tubular basement-membrane defects cause hematuria and bilateral
renal cysts, and muscle basement-membrane involvement causes cramps with
elevated creatine kinase — together with intracranial aneurysms, these define
the HANAC (hereditary angiopathy with nephropathy, aneurysms, and muscle cramps)
end of the spectrum, most associated with exon 24-25 variants.
cell_types:
- preferred_term: kidney epithelial cell
term:
id: CL:0002518
label: kidney epithelial cell
evidence:
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The systemic angiopathy of the HANAC syndrome appears to affect both small vessels and large arteries."
explanation: Defines the HANAC systemic angiopathy affecting small and large vessels.
downstream:
- target: Hematuria
description: Glomerular basement-membrane defect produces micro- or macroscopic hematuria.
causal_link_type: DIRECT
evidence:
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The clinical renal manifestations of the HANAC syndrome in these families include hematuria and bilateral, large cysts."
explanation: Links the renal basement-membrane defect to hematuria and cysts.
phenotypes:
- category: Neurological
name: Porencephaly
description: >-
Fluid-filled cavities in the brain, typically the resorbed sequelae of
perinatal cerebral hemorrhage, and the hallmark severe-end phenotype. Clinically
manifests as infantile hemiparesis, seizures, and intellectual disability,
though it can occasionally be an incidental finding.
phenotype_term:
preferred_term: Porencephaly
term:
id: HP:0002132
label: Porencephalic cyst
evidence:
- reference: PMID:16107487
reference_title: "Novel mutations in three families confirm a major role of COL4A1 in hereditary porencephaly."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "This observation confirms COL4A1 as a major locus for genetic predisposition to perinatal cerebral haemorrhage and porencephaly"
explanation: Confirms COL4A1 as a major cause of hereditary porencephaly.
- reference: PMID:15905400
reference_title: "Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "approximately 18% of survivors had porencephaly."
explanation: Recapitulation of porencephaly in the Col4a1 mouse model.
- category: Neurological
name: Intracerebral hemorrhage
description: >-
Antenatal, perinatal, or later-life (often recurrent) intracerebral hemorrhage,
frequently precipitated by trauma, exertion, or anticoagulation. A history of
stroke (hemorrhagic or ischemic) was reported in about one sixth of carriers in
a systematic review.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Cerebral hemorrhage
term:
id: HP:0001342
label: Cerebral hemorrhage
evidence:
- reference: PMID:16598045
reference_title: "Role of COL4A1 in small-vessel disease and hemorrhagic stroke."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "predisposes both newborn and adult mice to intracerebral hemorrhage."
explanation: Establishes hemorrhage predisposition across ages.
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A history of stroke was reported in 9 subjects (17.3%); in 6 cases it was attributable to subcortical hemorrhage and in 3 cases it was attributable to lacunar infarction."
explanation: >-
Derived count: 9 of 52 carriers (17.3%) had a stroke, mostly hemorrhagic,
placing symptomatic hemorrhage in the OCCASIONAL (5-29%) band.
- category: Neurological
name: Infantile hemiparesis
description: >-
Hemiparesis presenting in infancy, one of the classic presenting signs of
COL4A1 porencephaly / small-vessel disease.
phenotype_term:
preferred_term: Infantile hemiparesis
term:
id: HP:0001269
label: Hemiparesis
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "small-vessel brain disease manifests as infantile hemiparesis, seizures, single or recurrent hemorrhagic stroke, ischemic stroke, and isolated migraine with aura."
explanation: GeneReviews lists infantile hemiparesis as a core manifestation.
- category: Neurological
name: Seizures
description: Seizures, commonly in the setting of porencephaly or hemorrhagic injury.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Porencephaly (fluid-filled cavities in the brain detected by CT or MRI) is typically manifest as infantile hemiparesis, seizures, and intellectual disability"
explanation: GeneReviews lists seizures among porencephaly manifestations.
- category: Neurological
name: Intellectual disability
description: Intellectual disability, often correlating with the extent of hemorrhagic brain injury.
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Porencephaly (fluid-filled cavities in the brain detected by CT or MRI) is typically manifest as infantile hemiparesis, seizures, and intellectual disability"
explanation: GeneReviews lists intellectual disability among porencephaly manifestations.
- category: Neurological
name: Ischemic stroke
description: >-
Lacunar (small deep) ischemic infarction, a component of the cerebral
small-vessel disease that can present in adulthood.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Lacunar ischemic stroke
term:
id: HP:0002140
label: Ischemic stroke
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "microbleeds that are usually subcortical (52.9%), lacunar infarction (13.5%), and dilated perivascular spaces (19.2%)."
explanation: >-
Derived count: lacunar infarction in 13.5% of carriers places ischemic stroke
in the OCCASIONAL (5-29%) band.
- category: Neurological
name: Leukoencephalopathy
description: >-
Diffuse periventricular leukoencephalopathy (leukoaraiosis), the most frequent
imaging finding, present even in some asymptomatic adult carriers.
frequency: FREQUENT
phenotype_term:
preferred_term: Diffuse leukoencephalopathy
term:
id: HP:0002352
label: Leukoencephalopathy
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Brain imaging showed frequent leukoaraiosis (63.5%),"
explanation: >-
Direct quantitative frequency: leukoaraiosis in 63.5% of carriers places it in
the FREQUENT (30-79%) band.
- category: Neurological
name: Cerebral microbleeds
description: Cerebral microbleeds, usually subcortical, a common radiologic marker of the small-vessel disease.
frequency: FREQUENT
phenotype_term:
preferred_term: Cerebral microbleed
term:
id: HP:0002170
label: Intracranial hemorrhage
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "microbleeds that are usually subcortical (52.9%),"
explanation: >-
Direct quantitative frequency: subcortical microbleeds in 52.9% of carriers,
in the FREQUENT (30-79%) band.
- category: Neurological
name: Migraine with aura
description: >-
Migraine, with and without aura, sometimes as an isolated adult presentation;
mean age at onset around 31 years in the systematic review.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Migraine with aura
term:
id: HP:0002077
label: Migraine with aura
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Migraine (with and without aura) was reported in 10 subjects, with a mean age at onset of 31.7."
explanation: >-
Derived count: migraine in 10 of 52 carriers (~19%) places it in the
OCCASIONAL (5-29%) band.
- category: Vascular
name: Intracranial aneurysm
description: >-
Intracranial (often carotid-siphon) aneurysms, usually asymptomatic and
particularly associated with the HANAC-cluster (exon 24-25) variants.
frequency: FREQUENT
phenotype_term:
preferred_term: Intracranial aneurysm
term:
id: HP:0004944
label: Dilatation of the cerebral artery
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Asymptomatic intracranial aneurysms were common (44.4% of 18 with angiography)."
explanation: >-
Direct quantitative frequency among the imaged subset: aneurysms in 44.4% of
the 18 carriers with angiography, in the FREQUENT (30-79%) band.
- category: Ocular
name: Axenfeld-Rieger anomaly
description: >-
Anterior-segment dysgenesis of the Axenfeld-Rieger type (iris anomalies,
posterior embryotoxon), part of the ocular-anomalies phenotype.
phenotype_term:
preferred_term: Axenfeld-Rieger anomaly
term:
id: HP:0001492
label: Axenfeld anomaly
evidence:
- reference: PMID:17696175
reference_title: "COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diffuse leukoencephalopathy associated with ocular malformations of the Axenfeld-Rieger type was observed in five individuals."
explanation: Documents the Axenfeld-Rieger anomaly in a COL4A1 family.
- category: Ocular
name: Cataract
description: >-
Congenital or acquired cataract, which may be isolated/nonsyndromic or part of
the anterior-segment dysgenesis; in fetuses, lens abnormalities plus intracranial
hemorrhage are a strong pointer to COL4A1.
phenotype_term:
preferred_term: Congenital cataract
term:
id: HP:0000519
label: Developmental cataract
evidence:
- reference: PMID:24374867
reference_title: "Fetal intracerebral hemorrhage and cataract: think COL4A1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We report two cases of prenatal ICH associated with cataract and suggest that COL4A1 mutation should be envisaged in fetuses with prenatal ICH, especially in the presence of lens abnormalities at ultrasound examination."
explanation: Associates cataract with prenatal COL4A1 disease.
- category: Ocular
name: Retinal arterial tortuosity
description: >-
Bilateral tortuosity of the second- and third-order retinal arterioles
(first-order vessels spared), which can bleed after minor trauma causing
transient visual loss.
phenotype_term:
preferred_term: Retinal arterial tortuosity
term:
id: HP:0000631
label: Retinal arterial tortuosity
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "variably associated with eye defects (retinal arterial tortuosity, Axenfeld-Rieger anomaly, cataract)"
explanation: GeneReviews lists retinal arterial tortuosity among the ocular defects.
- category: Ocular
name: Glaucoma
description: Secondary congenital or juvenile glaucoma arising from the anterior-segment dysgenesis.
phenotype_term:
preferred_term: Glaucoma
term:
id: HP:0000501
label: Glaucoma
evidence:
- reference: PMID:28237965
reference_title: "Genetic dissection of anterior segment dysgenesis caused by a Col4a1 mutation in mouse."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "COL4A1 mutations cause multi-system disorders in patients, including ASD (congenital cataracts, Axenfeld-Rieger's anomaly, Peter's anomaly and microphthalmia) and congenital or juvenile glaucoma."
explanation: Links COL4A1 to congenital/juvenile glaucoma.
- category: Renal
name: Hematuria
description: Micro- or macroscopic hematuria from glomerular basement-membrane involvement.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Hematuria
term:
id: HP:0000790
label: Hematuria
evidence:
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The clinical renal manifestations of the HANAC syndrome in these families include hematuria and bilateral, large cysts."
explanation: Documents hematuria as a renal manifestation.
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Systemic features are also frequent, affecting the eye (10/21, 47.6%), kidney (15.4%), and muscle (15.4%)."
explanation: >-
Derived count: kidney involvement in 15.4% of carriers places renal features in
the OCCASIONAL (5-29%) band.
- category: Renal
name: Renal cysts
description: Bilateral, often large renal cysts.
phenotype_term:
preferred_term: Renal cyst
term:
id: HP:0000107
label: Renal cyst
evidence:
- reference: PMID:18160688
reference_title: "COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "hematuria and bilateral, large cysts."
explanation: Documents bilateral renal cysts.
- category: Musculoskeletal
name: Muscle cramps
description: Painful muscle cramps, part of the HANAC constellation, with early onset in HANAC families.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Muscle cramps
term:
id: HP:0003394
label: Muscle spasm
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "systemic findings (kidney involvement, muscle cramps, cerebral aneurysms, Raynaud phenomenon, cardiac arrhythmia, and hemolytic anemia)"
explanation: GeneReviews lists muscle cramps among systemic findings.
- category: Musculoskeletal
name: Elevated creatine kinase
description: Elevated serum creatine kinase reflecting muscle basement-membrane involvement.
phenotype_term:
preferred_term: Elevated circulating creatine kinase concentration
term:
id: HP:0003236
label: Elevated circulating creatine kinase concentration
evidence:
- reference: PMID:22914737
reference_title: "COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets."
supports: SUPPORT
evidence_source: OTHER
snippet: "mutations in COL4A1 or COL4A2 are pleiotropic and contribute to a broad spectrum of disorders, including myopathy, glaucoma and hemorrhagic stroke."
explanation: >-
Supports myopathy within the COL4A1 spectrum; elevated creatine kinase is the
laboratory marker of that muscle involvement and is inferred from it, hence PARTIAL.
- category: Vascular
name: Raynaud phenomenon
description: Raynaud phenomenon, a recognized systemic feature.
phenotype_term:
preferred_term: Raynaud phenomenon
term:
id: HP:0030880
label: Raynaud phenomenon
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "systemic findings (kidney involvement, muscle cramps, cerebral aneurysms, Raynaud phenomenon, cardiac arrhythmia, and hemolytic anemia)"
explanation: GeneReviews lists Raynaud phenomenon among systemic findings.
- category: Cardiovascular
name: Cardiac arrhythmia
description: Cardiac arrhythmia, a recognized systemic feature of the spectrum.
phenotype_term:
preferred_term: Arrhythmia
term:
id: HP:0011675
label: Arrhythmia
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "cardiac arrhythmia, and hemolytic anemia"
explanation: GeneReviews lists cardiac arrhythmia among systemic findings.
- category: Hematologic
name: Hemolytic anemia
description: Hemolytic anemia, a recognized systemic feature of the spectrum.
phenotype_term:
preferred_term: Hemolytic anemia
term:
id: HP:0001878
label: Hemolytic anemia
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "cardiac arrhythmia, and hemolytic anemia"
explanation: GeneReviews lists hemolytic anemia among systemic findings.
imaging_findings:
- name: Small-vessel disease on brain MRI
description: >-
Diffuse periventricular leukoencephalopathy, lacunar infarcts, microhemorrhage,
dilated perivascular spaces, deep intracerebral hemorrhages, and porencephalic
cavities are the characteristic MRI features. Extensive leukoaraiosis can be
present in asymptomatic adult carriers.
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "small-vessel brain disease is manifest as diffuse periventricular leukoencephalopathy, lacunar infarcts, microhemorrhage, dilated perivascular spaces, and deep intracerebral hemorrhages."
explanation: GeneReviews enumerates the imaging spectrum.
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "dilated perivascular spaces (19.2%)."
explanation: Quantifies dilated perivascular spaces among carriers.
environmental:
- name: Environmental "second hit" precipitants of hemorrhage
description: >-
Constitutional vascular fragility is converted to overt hemorrhage by
environmental stressors. In humans and mouse models these include birth
(delivery) trauma, head trauma, intense physical activity, anticoagulant
exposure, and hypertension. Avoiding these is the cornerstone of management.
evidence:
- reference: PMID:15905400
reference_title: "Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "we propose that Col4a1 mutations conspire with environmental trauma in causing the disease."
explanation: Establishes the gene-environment (second-hit) model.
- reference: PMID:25753534
reference_title: "Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "environmental factors such as intense exercise or anticoagulant medication modulated disease severity"
explanation: Identifies specific environmental modifiers of severity.
diagnosis:
- name: COL4A1 molecular genetic testing
description: >-
Diagnosis rests on clinical/imaging findings plus molecular genetic testing of
COL4A1 (and COL4A2). Because most variants are private missense substitutions,
sequencing is the mainstay; a compatible small-vessel-disease MRI pattern with
ocular or systemic features should prompt testing.
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Diagnosis is based on clinical findings and molecular genetic testing of COL4A1."
explanation: GeneReviews diagnostic principle.
- name: Fetal/neonatal imaging clue
description: >-
In the fetus or neonate, intracranial hemorrhage together with cataract or other
lens abnormalities on ultrasound is a specific pointer to a COL4A1 mutation.
evidence:
- reference: PMID:24374867
reference_title: "Fetal intracerebral hemorrhage and cataract: think COL4A1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "COL4A1 mutation should be envisaged in fetuses with prenatal ICH, especially in the presence of lens abnormalities at ultrasound examination."
explanation: Establishes the prenatal ICH-plus-cataract diagnostic clue.
treatments:
- name: Supportive and Symptomatic Care
description: >-
No disease-modifying therapy exists; management is supportive and tailored to
the individual's manifestations (rehabilitation after stroke, antiseizure
medication, cataract/glaucoma treatment, nephrology follow-up), with practical
and emotional support for affected individuals and families.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: supportive care
term:
id: NCIT:C15747
label: Supportive Care
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Supportive care tailored to the individual’s specific medical needs and including practical help and emotional support for affected individuals and their families."
explanation: GeneReviews management principle.
- name: Blood-Pressure Control and Stroke-Risk Reduction
description: >-
Hypertension should be treated to reduce the overall risk of stroke, and
smoking should be stopped, since both increase hemorrhagic and ischemic risk in
fragile vessels.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Hypertension should be treated to reduce the overall risk of stroke."
explanation: GeneReviews antihypertensive management recommendation.
- name: Avoidance of Hemorrhage Precipitants
description: >-
A specific, actionable management point: avoid anticoagulant exposure, head
trauma, and activities causing sustained head pressure, and control hypertension
and smoking. Avoiding head trauma and anticoagulants may decrease the risk of
intracerebral hemorrhage. Cesarean delivery is recommended for at-risk
pregnancies to avoid birth trauma.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: supportive care
term:
id: NCIT:C15747
label: Supportive Care
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Avoiding head trauma and anticoagulant exposure may decrease the risk for intracerebral hemorrhage."
explanation: GeneReviews prevention recommendation (agents/circumstances to avoid).
- reference: PMID:16598045
reference_title: "Role of COL4A1 in small-vessel disease and hemorrhagic stroke."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Surgical delivery of mutant mice alleviated birth-associated trauma and hemorrhage."
explanation: Preclinical basis for cesarean delivery to avoid birth-trauma hemorrhage.
- name: Genetic Counseling
description: >-
Autosomal dominant counseling with a 50% transmission risk; at least 27% of
cases are de novo. Variable expressivity and reduced penetrance complicate
prediction, and prenatal testing is possible when the familial variant is known.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: genetic counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:20301768
reference_title: "COL4A1-Related Disorders."
supports: SUPPORT
evidence_source: OTHER
snippet: "Each child of an individual with a COL4A1-related disorder has a 50% chance of inheriting the pathogenic variant."
explanation: Recurrence risk for genetic counseling.
- name: Chemical Chaperone (Investigational)
description: >-
Because intracellular collagen retention with ER stress is a key disease
mechanism, chemical chaperones that reduce intracellular accumulation are an
investigational, mechanism-directed strategy. In patient cells and in Col4a1/2
mutant mice, an FDA-approved chemical chaperone decreased intracellular collagen
accumulation; this is preclinical, not approved for the disease.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
target_mechanisms:
- target: Impaired Collagen IV Secretion and ER Stress
treatment_effect: INHIBITS
description: >-
Chemical chaperones promote proper folding/clearance of mutant collagen,
reducing ER accumulation and stress.
evidence:
- reference: PMID:24001601
reference_title: "Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "treatment of patient cells with a chemical chaperone decreased intracellular COL4A2"
explanation: >-
Cellular proof-of-concept for chemical-chaperone rescue of collagen retention;
shown for a COL4A2 variant, applicable to COL4A1 via the obligate shared
heterotrimer.
- reference: PMID:25753534
reference_title: "Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "treatment of mutant mice with a US Food and Drug Administration-approved chemical chaperone resulted in a decreased collagen"
explanation: In vivo proof-of-concept for chemical-chaperone reduction of collagen accumulation.
prevalence:
- population: Worldwide
measure_type: UNKNOWN
prevalence_class: ULTRA_RARE
notes: >-
A precise population prevalence has not been established; the disorder is rare,
with fewer than 100 families formally described at the time of the GeneReviews
chapter, and cumulative literature reporting several hundred patients and >70
variants. In ascertained cohorts, COL4A1/COL4A2 variants account for a minority
of pediatric porencephaly/childhood cerebral hemorrhage and of sporadic adult
intracerebral hemorrhage cases.
evidence:
- reference: PMID:25719457
reference_title: "The expanding phenotype of COL4A1 and COL4A2 mutations: clinical data on 13 newly identified families and a review of the literature."
supports: SUPPORT
evidence_source: OTHER
snippet: "COL4A1 and COL4A2 mutations have been reported with a broader spectrum of cerebrovascular, renal, ophthalmological, cardiac, and muscular abnormalities"
explanation: >-
Establishes the disorder as a rare but multi-system Mendelian entity; a precise
population rate is not quantified, hence measure_type UNKNOWN.
progression:
- phase: Prenatal / perinatal
age_range: In utero to neonatal
notes: >-
Intracranial hemorrhage can occur antenatally (detectable on fetal ultrasound)
or perinatally, precipitated by delivery, producing porencephaly, infantile
hemiparesis, and seizures at the severe end.
evidence:
- reference: PMID:24374867
reference_title: "Fetal intracerebral hemorrhage and cataract: think COL4A1."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "several authors have reported mutations in COL4A1 as a Mendelian cause of prenatal onset intracranial hemorrhage (ICH)."
explanation: Documents the prenatal/perinatal onset window.
- phase: Adulthood
age_range: Adult
notes: >-
In milder cases the disease presents in adulthood as small-vessel disease —
ischemic or hemorrhagic stroke (mean stroke onset ~36 years), migraine,
leukoencephalopathy, and aneurysms — sometimes as the first manifestation.
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "have been recently recognized as a further monogenic cause of small vessel disease that can present in adulthood."
explanation: Documents adult-onset small-vessel-disease presentation.
differential_diagnoses:
- name: Other hereditary cerebral small-vessel diseases
description: >-
CADASIL (NOTCH3), CARASIL (HTRA1), and other monogenic small-vessel diseases
share leukoencephalopathy and stroke; the presence of porencephaly, ocular
anterior-segment anomalies, retinal arterial tortuosity, or the HANAC systemic
features (hematuria, renal cysts, muscle cramps, aneurysms) points to COL4A1.
evidence:
- reference: PMID:20558831
reference_title: "COL4A1 mutations as a monogenic cause of cerebral small vessel disease: a systematic review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A number of single gene disorders can cause cerebral small vessel disease."
explanation: Situates COL4A1 among the monogenic small-vessel diseases requiring differentiation.
discussions:
- discussion_id: bsvd1_intracellular_vs_extracellular_mechanism
kind: KNOWLEDGE_GAP
status: OPEN
prompt: >-
To what extent is COL4A1-related disease driven by intracellular collagen
retention with ER stress (gain of function) versus extracellular
basement-membrane insufficiency (loss of function), and does the balance differ
by tissue?
attaches_to:
- "pathophysiology#Impaired Collagen IV Secretion and ER Stress"
rationale: >-
Both arms are experimentally supported: pathogenic variants trigger ER stress
and the unfolded protein response, and intracellular accumulation in vascular
endothelial cells and pericytes is a key hemorrhage trigger in mice; yet the
same variants also reduce secretion of functional collagen IV into the basement
membrane. The relative contribution matters therapeutically — a predominantly
intracellular mechanism favors chaperone/proteostasis strategies, whereas a
predominantly extracellular mechanism favors matrix-restoration or gene-based
approaches — and appears to vary by tissue. Resolving the balance per tissue is
an open question.
evidence:
- reference: PMID:22209247
reference_title: "COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Our data suggest that COL4A2 mutations impair COL4A1 and COL4A2 secretion and can also result in cytotoxicity."
explanation: >-
Documents both the secretion-impairment and cytotoxicity arms in COL4A2,
applicable to COL4A1 via the obligate shared heterotrimer, framing the open
question.
notes: >-
Curated from the COL4A1-Related Disorders GeneReviews chapter (PMID:20301768) plus
primary genetics, neuropathology, mouse-model, and cellular-mechanism literature,
cross-checked against a claude_code deep-research report (the falcon/Edison and
OpenScientist providers were unavailable at curation time — Edison returned an
auth error). MONDO:0008289 (OMIM:175780) is the cerebrovascular-predominant BSVD1
node of the broader COL4A1 spectrum; the isolated ocular forms are curated
separately (see Retinal_Arterial_Tortuosity), and the HANAC systemic constellation
is represented here as the renal/muscular/aneurysmal arm rather than as a separate
entry. Frequencies are drawn from the Lanfranconi & Markus systematic review of 52
carriers (PMID:20558831); because that cohort is ascertained, the bands are best
read as lower bounds on the imaged/symptomatic population. Deferred to follow-up
passes (real but not curated here for lack of a verified quotable frequency at
curation time): facial paresis, mitral valve prolapse, unilateral renal atrophy
with progressive GFR decline, and the zebrafish mmp9 and
gene-therapy-parameterization model threads described in the deep-research report.
Overview. Brain Small Vessel Disease 1 With or Without Ocular Anomalies (BSVD1) is an autosomal dominant, multisystem vascular basement-membrane disorder caused by heterozygous pathogenic variants in COL4A1 (collagen type IV alpha 1 chain), which encodes a principal structural component of essentially all basement membranes. The disorder centers on small-vessel cerebrovascular fragility — producing porencephaly, intracerebral hemorrhage, and leukoencephalopathy across the lifespan — but is highly pleiotropic, variably co-occurring with ocular anomalies (retinal arterial tortuosity, Axenfeld-Rieger anomaly, cataract), renal disease, muscle cramps/elevated creatine kinase, cardiac arrhythmia, Raynaud phenomenon, and hemolytic anemia. It sits on a phenotypic continuum with the allelic disorders HANAC syndrome (Hereditary Angiopathy with Nephropathy, Aneurysms, and muscle Cramps) and familial porencephaly, and together with COL4A2-related disease (BSVD2) is increasingly referred to in the literature as "Gould syndrome" (after Douglas B. Gould, who characterized the founding mouse model) (PubMed: 38355202; Gould Syndrome Foundation).
Key identifiers: - OMIM: #175780 — Brain Small Vessel Disease 1 With or Without Ocular Anomalies (BSVD1); gene locus COL4A1, OMIM 120130 (OMIM 175780; OMIM 120130) - MONDO: MONDO:0008289 (per GTR/MONDO cross-reference) - Gene: COL4A1, HGNC:2202, chromosome 13q34, NCBI Gene ID 1282 - Orphanet: Orphanet lists overlapping entries for COL4A1-related brain small-vessel disease, HANAC syndrome, and familial porencephaly (search GeneReviews/Orphanet cross-refs) - GeneReviews: "COL4A1-Related Disorders" (NBK7046) — the authoritative clinical reference (GeneReviews NBK7046) - ICD-10/11: No dedicated code; typically coded under cerebrovascular disease (I67.8/I67.9) or congenital cerebral anomaly codes plus phenotype-specific codes - Allelic/related entries: BSVD2 (COL4A2, OMIM #614483); HANAC syndrome (same gene, distinct exon cluster); autosomal dominant porencephaly type 1
Synonyms/alternative names: COL4A1-related disorder(s); COL4A1 syndrome; Gould syndrome; hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC, for the systemic-predominant end of the spectrum); familial porencephaly (older, phenotype-first terminology); autosomal dominant brain small-vessel disease with hemorrhage.
Evidence base. Information is derived from aggregated disease-level resources (OMIM, GeneReviews, Orphanet), pooled case-series/cohort literature (largest single series: 13 new families plus literature review, n>trend toward >350 patients and >70 variants reported cumulatively — PMID: 25719457), and individual case reports (particularly for prenatal/fetal presentations), supplemented by extensive mouse, zebrafish, Drosophila, and C. elegans mechanistic/model-organism studies.
Disease causal factor: Monogenic — heterozygous (dominant) pathogenic variant in COL4A1 is both necessary and sufficient to cause disease; this is a purely genetic etiology (no infectious or purely environmental primary cause), though environmental "second hits" strongly modulate expressivity (see below).
Genetic risk factors: - Causal variants: ~90% of pathogenic COL4A1 variants are missense substitutions of glycine residues within the Gly-X-Y repeat collagenous triple-helical domain, which disrupt proper triple-helix folding (dominant-negative/anti-morphic mechanism) (PMID: 22914737; GeneReviews NBK7046). Other variant classes: nonsense variants, splice-site variants causing in-frame exon skipping, small intragenic indels, a start-codon variant (p.Met1Leu), and a small duplication in the C-terminal NC1 domain. No recurrent whole-gene deletions/duplications have been reported. - Genotype-phenotype correlation (locus effect): Variants clustering in exons 24–25 (a ~30-amino-acid region) are specifically associated with the HANAC systemic/renal/muscular/ocular phenotype with lower hemorrhagic-stroke penetrance, whereas variants distributed across exons 25–51 are more associated with severe porencephaly/small-vessel brain disease (GeneReviews NBK7046; PMID: 19949034; PMID: 20818663). - Modifier genes: No confirmed modifier loci in humans; mouse genetic-background studies show strong strain-dependent modulation of penetrance/severity (below). - De novo occurrence: Roughly 25–42% of cases arise de novo depending on the cohort (Meuwissen et al. report 25% de novo, 50% inherited, 25% indeterminate — PMID: 25719457; other pediatric hemorrhage/porencephaly cohorts report up to 42% de novo). - Allelic gene: COL4A2 causes a closely overlapping phenotype (BSVD2, familial porencephaly type 2; PMID: 22209246) because COL4A1 and COL4A2 obligately co-assemble into the [α1(IV)]₂α2(IV) heterotrimer.
Environmental risk factors / "second hits" (gene-environment interaction): This is the best-characterized gene-environment interaction in the small-vessel-disease literature: - Birth trauma / mode of delivery: Vaginal delivery and instrumented delivery substantially increase risk of perinatal/neonatal intracerebral hemorrhage in COL4A1 mutation carriers; in the Col4a1 mouse model, "surgical delivery of Col4a1 mutant pups greatly reduced the incidence of perinatal ICH" (Hum Mol Genet review, PMID: 22914737). - Head trauma at any age, even minor, can trigger hemorrhage. - Anticoagulant/antiplatelet exposure increases hemorrhagic stroke risk and is specifically flagged as an agent to avoid (GeneReviews NBK7046). - Hypertension is a major modifiable risk factor for both hemorrhagic and ischemic events and is the single most emphasized target of clinical management. - Smoking increases stroke risk in this population per GeneReviews management guidance. - Perinatal/prenatal period functions as a specific vulnerability window: intracranial hemorrhage can occur in utero, detectable on fetal ultrasound as early as ~22–26 weeks gestation (PMID: 24374867), and pregnancy/delivery management is a key clinical decision point.
Protective factors: No specific protective genetic variants or environmental/dietary protective factors have been established in the literature. The principal "protective" interventions identified to date are iatrogenic/preventive (cesarean delivery, trauma avoidance, blood-pressure control, anticoagulant avoidance) rather than intrinsic biological protective factors.
Phenotype categories span clinical signs/symptoms, imaging findings, and laboratory abnormalities, with substantial inter- and intrafamilial variability in age of onset and severity (GeneReviews NBK7046).
| Phenotype | HPO suggestion | Onset | Severity/course | Frequency notes |
|---|---|---|---|---|
| Porencephaly (fluid-filled cerebral cavity from resorbed hemorrhage) | HP:0002132 (Porencephalic cyst) | Prenatal–infantile | Variable; can be unilateral or bilateral | Hallmark severe-end phenotype |
| Intracerebral/intracranial hemorrhage (antenatal, neonatal, or later-life recurrent) | HP:0001342 (Intracranial hemorrhage) | Any age (prenatal through late adulthood) | Recurrent; can be catastrophic or asymptomatic-on-imaging | Present across the spectrum; incidence ~6% in sporadic adult ICH cohorts, ~13% in porencephaly/childhood-hemorrhage cohorts |
| Periventricular leukoencephalopathy | HP:0002518 (Diffuse leukoencephalopathy) or HP:0006970 | Variable | Progressive on imaging | Common radiologic finding |
| Lacunar infarcts / ischemic stroke | HP:0002140 (Cerebral ischemia) | Adult (can be earlier) | Recurrent | Reported across cohorts |
| Cerebral microbleeds / dilated perivascular (Virchow-Robin) spaces | HP:0410282 or descriptive | Any age | Progressive | Common radiologic marker of small-vessel disease |
| Infantile hemiparesis/hemiplegia | HP:0001269 / HP:0004374 | Infantile | Static-to-variable | Common presenting sign in severe cases |
| Seizures | HP:0001250 | Infantile–childhood | Variable | Frequent |
| Intellectual disability / developmental delay | HP:0001249 / HP:0001263 | Childhood | Variable severity | Reported in a subset, often correlating with hemorrhage extent |
| Migraine with aura | HP:0002076 | Adult | Episodic | Reported as an isolated adult presentation in some families |
| Facial paresis | HP:0011800 (or specific facial palsy term) | Variable | — | Reported feature |
| Intracranial aneurysm (carotid siphon) | HP:0004944 | Adult | Often asymptomatic | Particularly associated with HANAC-cluster variants |
| Phenotype | HPO suggestion | Notes |
|---|---|---|
| Retinal arterial/arteriolar tortuosity (2nd/3rd order vessels) | HP:0025590 (Retinal arteriolar tortuosity) or HP:0000577-adjacent | Bilateral; first-order arteries and veins spared; can cause transient visual loss from spontaneous retinal hemorrhage after minor trauma |
| Axenfeld-Rieger anomaly (iris anomalies, posterior embryotoxon, microcornea) | HP:0000315 (Axenfeld-Rieger anomaly) | Anterior segment dysgenesis |
| Congenital or acquired cataract | HP:0000518 (Cataract) | Can be isolated/nonsyndromic or syndromic |
| Glaucoma | HP:0000501 | Secondary to anterior segment dysgenesis |
| System | Phenotype | HPO suggestion |
|---|---|---|
| Renal | Microscopic/gross hematuria; bilateral cortico-medullary cysts; unilateral renal atrophy; progressive GFR decline (typically >age 40) | HP:0000790 (Hematuria); HP:0000108 (Renal corticomedullary cysts) |
| Muscular | Elevated serum creatine kinase; painful muscle cramps (onset <age 3 in HANAC) | HP:0003236 (Elevated CK); HP:0003394 (Muscle cramps) |
| Cardiac | Mitral valve prolapse; supraventricular arrhythmia | HP:0001634; HP:0001679 |
| Vascular/hematologic | Raynaud phenomenon; hemolytic anemia | HP:0100753; HP:0001878 |
Quality of life impact: Not systematically measured with validated instruments (EQ-5D/SF-36) in this rare-disease population per the literature reviewed; qualitatively, impact is driven primarily by stroke-related disability (hemiparesis, epilepsy, cognitive impairment) in early-onset/severe cases, and by chronic disease surveillance burden (recurring MRI/aneurysm screening, nephrology/ophthalmology follow-up) even in mildly affected or presymptomatic carriers. The 2024 Gould Syndrome Foundation "disease concept model" work specifically calls out the need for patient/family-reported outcome data (Genetics in Medicine Open, P294, 2023).
Causal gene: COL4A1 (HGNC:2202; OMIM *120130), chromosome 13q34, 52 exons spanning ~158 kb, encoding the α1 chain of type IV collagen (procollagen).
Variant classification/type: - ~90% missense (glycine substitutions within Gly-X-Y repeats of the ~1,400-residue collagenous triple-helical domain), classified pathogenic/likely pathogenic per ACMG/AMP criteria in ClinVar - Nonsense variants - Splice-site variants (causing in-frame exon skipping at the cDNA level) - Small intragenic insertions/deletions - One reported start-codon variant (p.Met1Leu) - A small duplication in the C-terminal NC1 (non-collagenous) trimerization domain - Illustrative pathogenic variants curated in GeneReviews: c.1493G>T (p.Gly498Val), c.1555G>A (p.Gly519Arg), c.3706G>A (p.Gly1236Arg), c.4582_4586dupCCCAT (p.Met1529IlefsTer15), c.4738G>C (p.Gly1580Arg). ClinVar carries numerous additional variants explicitly classified against "Brain small vessel disease 1 with or without ocular anomalies" (e.g., RCV002247362 p.Gly749Ser, RCV002248564 p.Gln985His). - Molecular genetic testing yield: sequence analysis of COL4A1 detects the causative variant in essentially 100% of molecularly confirmed probands (GeneReviews NBK7046); no common exon-level deletion/duplication has been reported, so gene-targeted dosage analysis has low incremental yield.
Allele frequency: COL4A1 pathogenic variants are private/family-specific (ultra-rare), essentially absent from population databases (gnomAD) as heterozygous loss-of-function/glycine-substitution variants at appreciable frequency, consistent with a dominant, penetrant, disease-causing mechanism rather than a common susceptibility allele.
Somatic vs. germline: Germline (constitutional) heterozygous variant in essentially all reported cases; germline mosaicism is theoretically possible (invoked to explain apparent non-penetrance in a transmitting parent) but not confirmed in the literature reviewed.
Functional consequence / mechanism (dominant-negative / anti-morphic): - Type IV collagen α1 and α2 chains normally co-assemble as [α1(IV)]₂α2(IV) heterotrimeric protomers within the endoplasmic reticulum before secretion and incorporation into basement membranes. - Glycine substitutions destabilize the triple helix, causing intracellular retention of mutant heterotrimers, in some cases triggering an ER stress response (unfolded protein response activation) (PMID: 22914737; PMID: 26839400 — renal-specific ER stress + basement-membrane-defect dual mechanism in mouse). - Disease requires the presence of the mutant protein (anti-morphic/neomorphic effect) rather than simple haploinsufficiency — i.e., it is not solely a loss-of-function mechanism. - Reduced/defective heterotrimer secretion leads to basement membrane structural defects: focal interruptions, and thickened/fragmented capillary basement membranes on tissue biopsy. - These structural and cell-autonomous defects perturb cell-matrix signaling through integrin and other basement-membrane receptor pathways, compromising vascular smooth muscle/endothelial/pericyte support and increasing vessel fragility.
Modifier genes: No human modifier genes are firmly established; mouse studies show strong genetic-background (strain) modification of penetrance and severity of the perinatal hemorrhage phenotype, implying polygenic modifiers exist but are uncharacterized in humans.
Epigenetic information: No disease-specific DNA methylation/histone modification studies were identified in the literature reviewed; this remains an open area.
Chromosomal abnormalities: Not a copy-number/structural-rearrangement disease; standard cytogenetic/CMA findings are not causally implicated. COL4A1 and COL4A2 are arranged head-to-head on 13q34, sharing a bidirectional promoter — a structural genomic feature relevant to gene regulation but not itself pathogenic.
Causal chain (upstream → downstream):
Molecular pathways: Collagen IV network assembly/secretion pathway (ER protein-folding quality control, COPII-mediated ER-to-Golgi trafficking); cell-matrix integrin signaling; angiogenesis/vascular basement membrane remodeling pathways (implicated by zebrafish data showing elevated mmp9 transcription upon col4a1 loss, PMID: 40846110/41248836).
Cellular processes: ER stress/unfolded protein response; impaired secretion (proteostasis failure); basement membrane assembly and turnover; vascular smooth muscle cell/pericyte-endothelial basement membrane interaction; possible secondary apoptosis/cell death in stressed cell populations (renal tubular epithelium per mouse model, PMID: 26839400).
Protein dysfunction: Dominant-negative/anti-morphic protein misfolding causing intracellular retention rather than simple loss-of-function — a key distinguishing mechanistic feature from purely haploinsufficient basement-membrane disorders.
Immune system involvement: Not a primary autoimmune/immune-mediated mechanism; no significant literature support for immune dysregulation as a driver (contrast with COL4A3/A4/A5 Goodpasture/Alport spectrum, where autoimmunity/immune complex mechanisms can be relevant in related but distinct collagen IV chains).
Tissue damage mechanisms: Mechanical fragility leading to hemorrhage (rather than classic ischemia-reperfusion or fibrotic mechanisms as the primary driver), compounded by developmental basement-membrane insufficiency during angiogenesis in the perinatal period.
Biochemical abnormalities: Elevated serum creatine kinase (muscle basement membrane/sarcolemmal involvement); hematuria (glomerular basement membrane defect).
Molecular profiling / advanced technologies: Mouse multimodal MRI (14.1 Tesla) across five distinct Col4a1 mutant strains has been used to correlate genotype with radiologic small-vessel-disease features (microbleeds, white matter change) reproducing the human imaging spectrum (PMC12647094). A C. elegans collagen IV fluorophore knock-in toolkit has revealed tissue-specific basement-membrane trimer diversity and turnover defects modeling Gould syndrome (PMC11917169). No large-scale human transcriptomic/proteomic/metabolomic disease-tissue dataset was identified in this search — this remains an area lacking dedicated omics characterization in patients.
Suggested GO terms: GO:0005587 (collagen type IV trimer), GO:0030935 (collagen type IV binding, if applicable), GO:0007566 (embryo implantation - not relevant), more relevantly GO:0030198 (extracellular matrix organization), GO:0034976 (response to endoplasmic reticulum stress), GO:0001525 (angiogenesis), GO:0071711 (basement membrane organization). Suggested CL terms: CL:0000359 (vascular associated smooth muscle cell), CL:0000115 (endothelial cell), CL:0000669 (pericyte), CL:0000653 (podocyte, for renal involvement).
Organ level: - Primary: Brain (cerebral small vessels — arterioles, capillaries, venules), eye (retina, anterior segment: iris, cornea, lens) - Secondary/systemic: Kidney (glomerular/tubular basement membrane, renal cysts), skeletal muscle (sarcolemmal basement membrane), heart (mitral valve, conduction system), skin/peripheral vasculature (Raynaud phenomenon), blood (hemolytic anemia — likely microangiopathic/mechanical red cell fragmentation related to vessel wall abnormality) - Body systems: Nervous, ocular, renal/urinary, musculoskeletal, cardiovascular, hematologic
Tissue/cell level: - Vascular basement membrane (endothelial and vascular smooth muscle cell/pericyte-associated) — UBERON:0002049 (blood vessel), UBERON:0006798 (vascular basement membrane component context) - Cerebral microvasculature — UBERON:0002037 (cerebellum not relevant; use UBERON:0000955 brain, UBERON:0001383 middle cerebral artery / small vessel context) - Retinal vasculature — UBERON:0001782 (retinal vein)/UBERON:0001777 (retinal artery) - Glomerular basement membrane — UBERON:0000074 (renal glomerulus) - Cell populations of interest (Cell Ontology): vascular smooth muscle cell (CL:0000359), pericyte (CL:0000669), vascular endothelial cell (CL:0000115), podocyte (CL:0000653), astrocyte (secondary, in context of leukoencephalopathy — CL:0000127)
Subcellular level: Endoplasmic reticulum (site of collagen misfolding/retention and ER stress; GO:0005783 endoplasmic reticulum), extracellular matrix/basement membrane proper (GO:0005604 basement membrane).
Localization: Cerebral basement membranes are diffusely affected (periventricular white matter, deep gray/white junction — the classic small-vessel-disease distribution) rather than restricted to a single vascular territory. Retinal involvement is bilateral. Renal cysts are typically bilateral, cortico-medullary. Lateralization of porencephalic cavities is variable — can be unilateral or bilateral, reflecting the stochastic nature of the perinatal hemorrhagic insult rather than a deterministic laterality.
Onset: - Can be congenital/prenatal (fetal intracranial hemorrhage detectable by ultrasound as early as 22–26 weeks gestation; PMID: 24374867) - Neonatal/infantile (hemiparesis, seizures presenting in infancy following perinatal hemorrhage) - Adult-onset (first manifestation in previously asymptomatic adults — isolated migraine with aura, sporadic late-onset ICH, or incidental imaging findings) - Onset pattern is best described as variable/insidious-to-acute, with the acute hemorrhagic events being abrupt but superimposed on a lifelong, often subclinical, structural vulnerability.
Progression: - Radiologic small-vessel disease markers (periventricular leukoencephalopathy, microbleeds, dilated perivascular spaces) are generally progressive over time, even when clinically silent. - Clinical course is best characterized as episodic/recurrent for the hemorrhagic/ischemic stroke component (discrete events against a background of progressive imaging burden) rather than smoothly progressive. - No formal staging system (analogous to cancer staging) exists for this disorder. - Renal involvement (GFR decline) is typically slowly progressive, usually not clinically significant until after age 40.
Patterns: - No spontaneous remission pattern is described — this is a structural/genetic vulnerability rather than a fluctuating inflammatory process. - Critical vulnerability windows: the perinatal period (delivery-associated trauma) is the single most important identified critical period, directly motivating the clinical recommendation for cesarean delivery in known carriers to reduce birth-trauma-triggered hemorrhage. - Penetrance is described as "probably close to 100%" for at least some manifestation of the phenotype, but age of first manifestation and severity are highly variable within and between families (GeneReviews NBK7046).
Epidemiology: - True population prevalence/incidence is not established — this is an ultra-rare disorder. GeneReviews states prevalence "cannot be established" because fewer than 100 families had been formally described at time of writing; more recent aggregate literature reviews report >350 patients and >70 pathogenic/likely pathogenic variants cumulatively reported (PMID: 25719457 and subsequent literature). - In specific ascertained cohorts: COL4A1/COL4A2 variants account for ~13% of pediatric porencephaly/childhood cerebral hemorrhage cases, and ~6% of sporadic adult-onset intracerebral hemorrhage cases (PMID: 22522439 for the adult ICH figure).
Inheritance pattern: Autosomal dominant.
Penetrance: Probably close to complete for some manifestation of the phenotype, but with substantial variability in which manifestation, age of onset, and severity ("variable expressivity" is the dominant genetic-counseling framing rather than incomplete penetrance per se).
Expressivity: Markedly variable — even within a single family carrying an identical variant, presentations range from asymptomatic incidental imaging findings in an adult to devastating perinatal porencephaly, reflecting the strong contribution of environmental "second hits" (birth trauma, head trauma, blood pressure) superimposed on the genetic lesion.
Genetic anticipation: Not described/reported for this disorder (this is not a repeat-expansion disease).
Germline mosaicism: Theoretically invoked to explain unaffected transmitting parents but not formally documented in the literature reviewed; GeneReviews notes it as a caveat when a proband appears de novo but a parent shows mild/subclinical findings on targeted evaluation.
De novo rate: ~25–42% depending on cohort, with the remainder inherited from an (sometimes only mildly or subclinically) affected parent.
Founder effects: No specific founder population/mutation has been described; variants are private and family-specific.
Consanguinity: Not relevant to this dominant disorder (in contrast to the rare recessive COL4A1-related encephalopathy reported in Turkish consanguineous families, which is phenotypically and mechanistically distinct — see Differential Diagnosis).
Carrier frequency: Not applicable in the traditional recessive-carrier-screening sense; each pathogenic variant is essentially unique to its family, precluding population carrier-frequency estimation.
Population demographics: Reported cases span Dutch, Italian, French, German, American, Chinese, Spanish, and Japanese ancestries, with no clear ethnic/geographic clustering identified — consistent with a private-variant, pan-ethnic disorder. No specific sex ratio skew has been reported (autosomal dominant, non-sex-linked). Age distribution at ascertainment spans fetal life through late adulthood, reflecting the wide phenotypic spectrum.
Clinical/laboratory tests: - Serum creatine kinase (elevated, especially in HANAC-spectrum cases) - Serum creatinine / renal function panel - Urinalysis for micro-/macroscopic hematuria
Imaging studies: - Brain MRI (protocol: T1 sagittal, T2 axial, FLAIR axial per GeneReviews) — identifies porencephaly, periventricular leukoencephalopathy, lacunar infarcts, microhemorrhage (best seen on susceptibility-weighted/GRE sequences), dilated perivascular spaces, and deep ICH - Brain CT angiography (CTA) or MRA — for intracranial (particularly carotid siphon) aneurysm screening, especially relevant in HANAC-spectrum variant carriers - Renal ultrasound or CT — for cortico-medullary cysts and renal atrophy - Fetal ultrasound — detects prenatal ICH, ventriculomegaly, porencephaly, and associated lens abnormalities; median gestational age at detection in mutation-positive cases (~22–26 weeks) is significantly earlier than in mutation-negative cases (~30–34 weeks) (search result synthesis of prenatal case series)
Functional/electrophysiologic tests: - EKG, and echocardiography if arrhythmia symptoms present (mitral valve prolapse, supraventricular arrhythmia surveillance)
Ophthalmologic examination: - Slit-lamp exam (anterior segment: iris, cornea, lens for Axenfeld-Rieger anomaly/cataract) - Dilated fundoscopy ± fluorescein angiography (retinal arterial tortuosity — typically no leakage/staining on angiography, distinguishing it from inflammatory/neovascular vasculopathies)
Genetic testing: - First-line: Single-gene sequence analysis of COL4A1 (detects ~100% of causative variants in molecularly confirmed cases) - Second-line if negative: Gene-targeted deletion/duplication analysis (low yield — no common CNVs reported), multigene panel including COL4A1/COL4A2 and small-vessel-disease-related genes (NOTCH3, HTRA1, TREX1) - Broader testing: Exome or genome sequencing when panel testing is uninformative, particularly for atypical or fetal presentations - Prenatal/preimplantation genetic testing: Available once a familial pathogenic variant is identified - Chromosomal microarray/karyotype/FISH: Not primarily indicated (not a CNV/structural disorder) but may be used to exclude differential diagnoses in undifferentiated prenatal ICH/porencephaly workups - Mitochondrial DNA testing / repeat expansion testing: Not applicable to this disorder specifically but may be part of a broader differential workup for undiagnosed cerebral small-vessel disease
Differential diagnosis (per GeneReviews): - COL4A2-related disorder (BSVD2) — clinically near-identical, distinguished only by molecular testing - CADASIL (NOTCH3) — typically mid-adult onset, characteristic electron-dense granular osmiophilic material (GOM) on skin biopsy electron microscopy - RVCL/HERNS (TREX1) — retinal vasculopathy with cerebral leukoencephalopathy - CARASIL (HTRA1, autosomal recessive) — primarily reported in Asian populations, alopecia and spondylosis as distinguishing extra-neurologic features - Coagulopathies (von Willebrand disease, Factor V/X deficiency, other thrombophilias) — for isolated hemorrhagic presentations without the syndromic ocular/renal/muscular features - A distinct, rare autosomal recessive COL4A1-related encephalopathy has also been reported (Turkish consanguineous families), mechanistically and inheritance-pattern-wise separate from the classic dominant BSVD1 entity (Neurology Genetics, NXG.0000000000000392)
Screening: No population-based newborn screening program exists (ultra-rare, and typically ascertained through symptomatic presentation or known family history). Targeted "cascade" screening (MRI, ophthalmologic exam, molecular testing) of first-degree relatives of a proband is recommended given the high rate of subclinical/asymptomatic disease in carriers.
Survival/mortality: No formal actuarial survival statistics or standardized mortality ratio were identified in the literature reviewed; mortality risk is event-driven (acute hemorrhagic stroke, particularly perinatal ICH, carries the highest immediate mortality/morbidity risk) rather than characterized by a chronic attrition curve. Perinatal cerebral hemorrhage can be fatal or severely disabling; later-onset disease is more often morbidity- than mortality-driving.
Morbidity/function: - Major long-term functional morbidity stems from early hemorrhagic injury: cerebral palsy-spectrum motor impairment, epilepsy, and intellectual disability in individuals with significant perinatal/infantile hemorrhage and porencephaly. - Progressive renal impairment (typically after age 40) contributes to chronic morbidity in a subset. - No validated disease-specific quality-of-life instrument was identified; QOL impact is inferred qualitatively from the neurologic disability burden.
Disease course/complications: - Recurrent stroke (hemorrhagic or ischemic) throughout life - Aneurysm-related risk (rupture risk managed via surveillance and threshold-based intervention, see Treatment) - Progressive white matter disease/leukoencephalopathy even in the absence of overt stroke events - Glaucoma as a complication of anterior segment dysgenesis - Cardiac arrhythmia as a chronic management issue
Prognostic factors: Severity of perinatal/early hemorrhagic injury is the single strongest determinant of long-term neurologic prognosis. Variant location (exon 24–25 HANAC cluster vs. broader exon 25–51 distribution) correlates with differing risk profiles (systemic/renal/aneurysmal vs. hemorrhagic stroke-predominant), functioning as a partial prognostic/genotype-phenotype marker (GeneReviews NBK7046; PMID: 19949034).
Prognostic biomarkers: No validated circulating or imaging biomarker for disease progression/treatment response currently exists; the 2025 gene-therapy development literature explicitly identifies the establishment of imaging-based and other biomarkers as an active, unmet need for future clinical trial design (MDPI Proceedings, Musolino 2025).
There is currently no disease-modifying or targeted therapy approved for COL4A1-related disorder; management is entirely risk-reduction and symptomatic/supportive, per GeneReviews and the 2024/2025 international consensus efforts.
Pharmacotherapy (symptomatic/risk-reduction): - Antihypertensive therapy to reduce hemorrhagic/ischemic stroke risk — MAXO:0000950 (supportive care) / NCIT:C15986 (Pharmacotherapy) framing; specific agent class not disease-specific - Antiseizure medications, standard protocols for seizure management (MAXO term: standard antiepileptic pharmacotherapy) - Beta-blockers or other antiarrhythmics for symptomatic cardiac arrhythmia - Topical anti-glaucoma medications for secondary glaucoma (MAXO:0000950-adjacent; specific ocular pharmacotherapy) - Pharmacogenomics: No COL4A1-specific pharmacogenomic guidance identified (not a drug-metabolism gene)
Surgical/interventional: - Cataract surgery for visually significant cataract (NCIT:C15329 Surgical Procedure / MAXO:0000004) - Glaucoma surgery for medication-refractory cases - Surgical/endovascular treatment of intracranial aneurysms meeting size threshold (>10 mm diameter per GeneReviews) — MAXO:0000004 (surgical procedure) / relevant endovascular NCIT term - Cesarean delivery recommended for pregnancies at risk (known maternal or fetal carrier status) specifically as birth-trauma-avoidance prophylaxis — a distinctive, disease-specific obstetric management recommendation
Supportive/rehabilitative care: - Standard post-stroke rehabilitation (physical therapy, occupational therapy, speech therapy as indicated) — MAXO:0000011 (physical therapy) - Nutritional/general supportive care as needed (MAXO:0000950)
Advanced/experimental therapeutics (active development, not yet clinically available): - Gene-targeted therapy is in active preclinical/early-translational development, discussed at the 2024 and 2025 COL4A1-COL4A2 International Conferences: - AAV-based, pericyte/vascular-smooth-muscle-cell-retargeted gene delivery and lipid nanoparticle delivery strategies aimed at restoring cerebrovascular basement membrane integrity (MDPI Proceedings 2025) - Targeted genome editing approaches are furthest advanced for the related small-vessel-disease gene ACTA2 (R179H variant), described as progressing toward IND-enabling studies — illustrative of the platform approach being extended to COL4A1/COL4A2, but COL4A1-specific editing therapeutics remain earlier-stage - Chemical chaperone and autophagy-inducing agent strategies (e.g., rapamycin-class autophagy inducers) are proposed based on C. elegans proof-of-concept data showing that promoting proper protein folding decreases intracellular mutant-protein accumulation and rescues viability in emb-9/let-2 (collagen IV) mutant worms (PMID: 22914737) - A multifunction murine Col4a1 allele has been engineered specifically to define gene-therapy parameters (timing, dose-response) for future translational work (PMID: 40279671)
Treatment strategy: No formal treatment algorithm/clinical pathway exists yet; the field is actively working toward consensus. The 2024 international expert consensus (survey-based, published in Genetics in Medicine 2025) explicitly states that "individualized treatment plans based on clinical presentation, regular monitoring, and supportive care are crucial," while encouraging enrollment in natural history registries in anticipation of future clinical trials (Genetics in Medicine 2025 consensus; Multiorgan manifestations/management protocol proposal, AJMG-C 2024).
Agents/exposures to avoid: Anticoagulants, activities with head-trauma risk, uncontrolled hypertension, smoking.
Mouse models (most extensively characterized): - Founding model: Col4a1 dominant, semidominant ENU-mutagenesis-derived mouse mutant reported by Gould et al. (2005), which established the causal, dominant, gain-of-function-like mechanism: "half of the mutant mice died with cerebral hemorrhage within a day of birth, and approximately 18% of survivors had porencephaly," with the vascular defect shown to be caused by a semidominant Col4a1 mutation that "inhibits the secretion of mutant and normal type IV collagen," and human COL4A1 variants shown to segregate with porencephaly in affected families (Science 2005; PMID: 15905400). - Anterior segment dysgenesis model: A distinct Col4a1 mutant mouse line demonstrates genetically dissociable ocular (anterior segment dysgenesis) and renal (glomerulopathy) phenotypes, useful for dissecting tissue-specific mechanism (Disease Models & Mechanisms, PMC5399567). - Renal-specific mechanism model: Demonstrates combined ER stress and basement membrane structural defects driving glomerular and tubular disease (PMID: 26839400). - Retinal model: Col4a1 mutant mice show progressive retinal neovascular defects and retinopathy, modeling the human ocular vascular phenotype (PMC4728690). - Stroke-prevention mechanism model: Multiple collagen type IV mutant mouse strains used to define molecular/genetic determinants of spontaneous ICH and identify stroke-prevention mechanisms, including the key finding that surgical (cesarean) delivery greatly reduces perinatal ICH incidence — directly informing human obstetric management (Circulation 2015; PMID: 25753534). - Neuromuscular phenotype model: Demonstrates tissue-specific mechanistic heterogeneity, showing that not all Col4a1 mutant alleles behave identically across tissues (ScienceDirect, 2019). - Multimodal imaging characterization: Five distinct Col4a1 mutant mouse strains subjected to 14.1T multimodal MRI to correlate allelic variation with radiologic small-vessel-disease features, directly modeling the clinical spectrum of "Gould syndrome" (PMC12647094). - Basement membrane developmental imaging tool: mTurq2-Col4a1 fluorescent knock-in mouse for live visualization of basement membrane deposition/dynamics during development (PMC10557719). - Gene-therapy parameterization model: A newly engineered multifunction murine Col4a1 allele designed specifically to define timing/dose parameters relevant to future gene-therapy development (PMID: 40279671, 2025). - Adult-onset microbleed model: A CRISPR/Cas9-mediated conditional Col4a1 deletion targeted to adult brain microvessels creates a novel model of cerebral microbleeds, separating adult-onset small-vessel pathology from developmental/perinatal mechanisms (bioRxiv 2025).
Zebrafish models: - col4a1 crispant/loss-of-function zebrafish larvae recapitulate spontaneous intracerebral hemorrhage and cerebrovascular abnormalities, with abnormal cerebrovascular basement membranes and elevated mmp9 transcription; these models enable in vivo functional assessment of human patient-derived COL4A1 variants, offering a rapid, optically tractable variant-classification platform (PMID: 40846110; PMID: 41248836, both 2025) — this is a notably recent (2025) and directly translationally relevant advance for variant curation.
C. elegans models: Type IV collagen homologs emb-9 (α1 ortholog) and let-2 (α2 ortholog) are required for muscle integrity/maintenance; mutants show contraction-induced muscle fiber rupture and embryonic lethality, and have been used for chemical-chaperone/proteostasis-modulator proof-of-concept rescue experiments relevant to future COL4A1 therapeutics. A recent fluorophore knock-in toolkit further resolves tissue-specific collagen IV trimer composition and basement membrane turnover defects (PMC11917169).
Drosophila models: Loss/reduction of the collagen IV-encoding gene Cg25C causes impaired muscle attachment; Col4a1-mutant flies show aberrant larval body wall muscle organization and centronuclear myopathy of oviduct muscles leading to progressive female infertility — a useful, genetically tractable system for dissecting basement-membrane/muscle-attachment mechanisms, complementary to the vascular focus of the mammalian models.
Model limitations: Mouse models robustly recapitulate the perinatal hemorrhage/porencephaly and progressive small-vessel disease phenotypes and have been the primary drivers of mechanistic and preclinical therapeutic insight, but tissue-specific mechanistic heterogeneity across mouse alleles (some drive ocular phenotypes without renal disease, or vice versa) indicates that no single existing model fully captures the entire human multisystem phenotype; zebrafish and invertebrate models are newer, rapid, and useful for variant functional classification and high-throughput chemical screening but have less-established fidelity to the full spectrum of human cerebrovascular pathology.